high mobility group box 1 pseudogene 20Genealiases: []
Q-omics provides the consensus-scored HMGB1P20 profile across patient tissues and cancer cell-line models. HMGB1P20 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HMGB1P20 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, HMGB1P20 RNA expression shows 13,486 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where HMGB1P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P20 survival associations across molecular data types. HMGB1P20 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P20 RNA expression–survival associations across cancer types. High HMGB1P20 expression shows unfavorable associations in UVM, ACC, LIHC, SKCM, GBM and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for HMGB1P20 RNA expression.
This table summarizes HMGB1P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P20 shows higher tumor expression in LIHC, COAD, BRCA, HNSC, READ and CHOL. The LIHC box plot shows higher HMGB1P20 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p < 0.001).
This table shows molecular features associated with HMGB1P20 in patient tissues and cancer cell lines. In patient samples, HMGB1P20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
